JP6889328B2 - 三次元構造に基づくヒト化方法 - Google Patents

三次元構造に基づくヒト化方法 Download PDF

Info

Publication number
JP6889328B2
JP6889328B2 JP2020505165A JP2020505165A JP6889328B2 JP 6889328 B2 JP6889328 B2 JP 6889328B2 JP 2020505165 A JP2020505165 A JP 2020505165A JP 2020505165 A JP2020505165 A JP 2020505165A JP 6889328 B2 JP6889328 B2 JP 6889328B2
Authority
JP
Japan
Prior art keywords
amino acid
human
score
acid residues
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530991A5 (https=
JP2020530991A (ja
Inventor
ヨハネス アウアー
ヨハネス アウアー
ギイ ゲオルゲス
ギイ ゲオルゲス
シュテファン クロステルマン
シュテファン クロステルマン
ヴォルフガング シェーファー
ヴォルフガング シェーファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2020530991A publication Critical patent/JP2020530991A/ja
Priority to JP2021085009A priority Critical patent/JP7217772B2/ja
Publication of JP2020530991A5 publication Critical patent/JP2020530991A5/ja
Application granted granted Critical
Publication of JP6889328B2 publication Critical patent/JP6889328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020505165A 2017-07-31 2018-07-27 三次元構造に基づくヒト化方法 Active JP6889328B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021085009A JP7217772B2 (ja) 2017-07-31 2021-05-20 三次元構造に基づくヒト化方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183933 2017-07-31
EP17183933.5 2017-07-31
PCT/EP2018/070372 WO2019025299A1 (en) 2017-07-31 2018-07-27 METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021085009A Division JP7217772B2 (ja) 2017-07-31 2021-05-20 三次元構造に基づくヒト化方法

Publications (3)

Publication Number Publication Date
JP2020530991A JP2020530991A (ja) 2020-11-05
JP2020530991A5 JP2020530991A5 (https=) 2021-05-27
JP6889328B2 true JP6889328B2 (ja) 2021-06-18

Family

ID=59649461

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505165A Active JP6889328B2 (ja) 2017-07-31 2018-07-27 三次元構造に基づくヒト化方法
JP2021085009A Active JP7217772B2 (ja) 2017-07-31 2021-05-20 三次元構造に基づくヒト化方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021085009A Active JP7217772B2 (ja) 2017-07-31 2021-05-20 三次元構造に基づくヒト化方法

Country Status (6)

Country Link
US (1) US11680110B2 (https=)
EP (1) EP3625254B1 (https=)
JP (2) JP6889328B2 (https=)
CN (2) CN117050176A (https=)
TW (1) TW201910515A (https=)
WO (1) WO2019025299A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111613275B (zh) * 2020-05-26 2021-03-16 中国海洋大学 一种基于rmsd多特征的药物分子动力学结果分析方法
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
CN118382639A (zh) 2021-08-06 2024-07-23 耶达研究发展公司 人源化抗体方法
CN116052760A (zh) * 2022-09-02 2023-05-02 北京中大唯信科技有限公司 基于三维结构的抗体人源化的方法
WO2025105282A1 (ja) * 2023-11-16 2025-05-22 国立大学法人熊本大学 抗体動的構造特性分析装置、抗体動的構造特性分析方法及びプログラム

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3306063B2 (ja) 1990-08-24 2002-07-24 イグジス， インコーポレイテッド ランダムコドンを有するオリゴヌクレオチドを合成する方法
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
EP0563296B1 (en) 1990-12-20 1999-03-17 Ixsys, Inc. Optimization of binding proteins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU6132994A (en) 1993-02-02 1994-08-29 Scripps Research Institute, The Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
JPH10185925A (ja) 1996-12-20 1998-07-14 Seibutsu Bunshi Kogaku Kenkyusho:Kk ダブル・ダイナミック・プログラミングによる構造アライメント方法
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
EP1028317A4 (en) 1997-10-02 2002-10-02 Akiko Itai METHOD FOR THE INTERFERENCE OF A THREE-DIMENSIONAL PROTEIN STRUCTURE
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
JPH11232291A (ja) 1998-02-16 1999-08-27 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質立体構造データベース検索方法
WO1999045959A1 (en) 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
CA2443862A1 (en) 2001-04-17 2002-10-24 Peizhi Luo Structure-based construction of human antibody library
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
CN101962408A (zh) * 2002-07-12 2011-02-02 杰斐逊·富特 超人源化抗体
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
EP1660970A4 (en) * 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
CA2600929A1 (en) * 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
US8343489B2 (en) 2006-03-21 2013-01-01 Weaver David T Methods for humanizing antibodies and humanized antibodies made thereby
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
WO2010065921A2 (en) 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2014100542A1 (en) * 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
ES2857553T3 (es) 2014-10-24 2021-09-29 Hoffmann La Roche Humanización de anticuerpos basada en ángulo interdominio VH-VL

Also Published As

Publication number Publication date
JP2021151236A (ja) 2021-09-30
EP3625254C0 (en) 2023-12-13
TW201910515A (zh) 2019-03-16
CN110945023B (zh) 2023-08-18
US20200223945A1 (en) 2020-07-16
WO2019025299A1 (en) 2019-02-07
EP3625254B1 (en) 2023-12-13
JP2020530991A (ja) 2020-11-05
CN117050176A (zh) 2023-11-14
EP3625254A1 (en) 2020-03-25
CN110945023A (zh) 2020-03-31
JP7217772B2 (ja) 2023-02-03
US11680110B2 (en) 2023-06-20

Similar Documents

Publication Publication Date Title
JP7217772B2 (ja) 三次元構造に基づくヒト化方法
JP6829194B2 (ja) Ｖｈ−ｖｌドメイン間角度に基づく抗体ヒト化の方法
JP7695881B2 (ja) 操作されたｃｄ２５ポリペプチドおよびその使用
US20040110226A1 (en) Antibody optimization
JP2007512846A (ja) 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
US20090130102A1 (en) Methods for humanizing antibodies and humanized antibodies made thereby
Townsend et al. Augmented binary substitution: single-pass CDR germ-lining and stabilization of therapeutic antibodies
JP7511561B2 (ja) エピトープおよびパラトープを同定する方法
Tennenhouse et al. Energy-guided combinatorial co-optimization of antibody affinity and stability
HK40098558A (zh) 基於三维结构的人源化方法
HK40023878B (zh) 基於三维结构的人源化方法
HK40023878A (en) Three-dimensional structure-based humanization method
CN101426526B (zh) 使用工程诱杀蛋白的液相生物淘选方法
HK40063170A (en) Methods for identifying epitopes and paratopes
HK40063514A (en) Engineered cd25 polypeptides and uses thereof
EA048641B1 (ru) Способы определения эпитопов и паратопов
HK1242352B (zh) 基於vh-vl域间角的抗体人源化
HK1242352A1 (en) Vh-vl-interdomain angle based antibody humanization

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210324

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210520

R150 Certificate of patent or registration of utility model

Ref document number: 6889328

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250